Publications by authors named "Sarath Lal Mannumbeth Renjithal"
Article Synopsis
- - Left atrial appendage closure (LAAC) helps prevent strokes in patients with atrial fibrillation, but peri-device leak (PDL) might increase the risk of thromboembolic events.
- - A systematic review of 54,279 patients from 11 studies revealed that PDL significantly raised the odds of experiencing strokes, transient ischemic attacks (TIAs), or systemic embolisms.
- - Despite the increased risk of thromboembolic events linked to PDL, the study found no significant differences in overall mortality, cardiovascular mortality, or ischemic strokes.
ORGANIZING PNEUMONIA: AN UNUSUAL SEQUELA OF COVID-19 INFECTION.
Lea Carina Rivera Sarah Mohamed Tooba Salar Mostafa Reda Mostafa Mostafa Najim Sarath Lal Mannumbeth Renjithal
Eur J Case Rep Intern Med
February 2023
Unlabelled: Organizing pneumonia (OP) is a form of interstitial lung disease that develops in response to acute lung injury. SARS-CoV-2 causes a wide range of lung and extrapulmonary disease, but there are few data suggesting an association between COVID-19 and OP. We describe a patient with COVID-19 pneumonia who developed severe progressive OP with significant morbidity.
View Article and Find Full Text PDFBackground: Left atrial (LA) appendage closure (LAAC) is effective in patients with atrial fibrillation who are not candidates for long-term anticoagulation. However, the impact of LAAC on LA function is unknown. The aim of this study is to evaluate the impact of LAAC on atrial function.
View Article and Find Full Text PDFArticle Synopsis
- Ischemic stroke due to atrial fibrillation can be prevented with anticoagulation, but some patients cannot use oral anticoagulants, making the WATCHMAN device a viable alternative that effectively reduces stroke risk.
- After the WATCHMAN procedure, patients typically receive warfarin and aspirin for 45 days, followed by adjustments based on follow-up tests, with some patients possibly only needing antiplatelet therapy if they have a high bleeding risk.
- Current practices often favor a regimen combining warfarin and antiplatelets, but more research is necessary to develop tailored antithrombotic strategies for those at elevated bleeding risk.